Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News and Analysis
  • Published:

Pioneering biased ligand offers efficacy with reduced on-target toxicity

Nature Reviews Drug Discovery volume 14, pages 809–810 (2015)Cite this article

Subjects

Clinical success with Trevena's 'biased' G protein-coupled receptor ligand highlights the potential of exploring the nuances of receptor pharmacology.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Two paths diverged.
Authors
  1. Katie Kingwell
    View author publications

    You can also search for this author in PubMed Google Scholar

PowerPoint slides

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kingwell, K. Pioneering biased ligand offers efficacy with reduced on-target toxicity. Nat Rev Drug Discov 14, 809–810 (2015). https://doi.org/10.1038/nrd4784

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd4784

This article is cited by

Search

Advanced search

Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research